Vela Technologies (GB:VELA) has released an update. Vela Technologies, an early-stage tech investment firm, has announced their stake in Conduit Ph…

Conduit Pharmaceuticals Inc. announced … myeloperoxidase inhibitor (MPO). AstraZeneca had progressed AZD1656 and … and AZD5904 from AstraZeneca to Conduit. AstraZeneca has been granted … special offers from American Pharmaceutical Review – all delivered right …

We recently compiled a list of the 10 Best GLP-1 and Weight Loss Stocks to Buy Now. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other GLP-1 and weight loss stocks. According to WHO, more than one billion people worldwide are obese, including 650 million adults, […]

… . 08.08.24 Conduit Pharmaceuticals Inc., which recently opened … into an agreement with AstraZeneca to exclusively license rights … of future sublicensing revenues. AstraZeneca will provide pre-clinical and … . Given the data from AstraZeneca ’s clinical trials, we …

Total income stood at Rs 396 crore for the June quarter against Rs 303 crore in the year-ago period, AstraZeneca Pharma India said in a regulatory filing

U.S. stocks traded higher this morning, with the S&P 500 gaining around 1% on Thursday. The Dow traded up 0.69% to 39,031.86 while the NASDAQ rose 1.33% to 16,411.69. The S&P 500 also rose, gaining, 1.07% to 5,255.11. Leading and Lagging Sectors Information technology shares climbed by 1.6% on Thursday. In trading on Thursday, utilities shares fell by 0.2%. Top Headline U.S. initial jobless claims declined by 17,000 to 230,000 in the week ending August 3, compared to market estimates of 240,000. Equities Trading UP Conduit Pharmaceuticals Inc. (NASDAQ: CDT ) shares shot up 100% to $0.3304 after the company announced it entered into an exclusive license agreement with AstraZeneca to develop AZD1656 and AZD5658. Shares of Comstock Inc. (NASDAQ: Full story available on Benzinga.com

No summary available.

Conduit Pharmaceuticals (CDT) has entered into an agreement with AstraZeneca to exclusively license rights to develop AZD1656 and AZD5658, both HK-4 glucokinase activators, and AZD5904, a myeloperoxidase inhibitor. AstraZeneca will grant Conduit an exclusive license to both AZD1656 and AZD5658 for all human indications, as well as an exclusive license to AZD5904 for use in Idiopathic Male Infertility.

Conduit Pharmaceuticals (NASDAQ: CDT ) stock is rocketing higher on Thursday after the clinical-stage specialty biopharmaceutical company announced an exclusive license agreement with AstraZeneca (NASDAQ: AZN ). This has Conduit Pharmaceuticals obtaining exclusive rights for three product candidates in development at AstraZeneca. That includes HK-4 glucokinase activators AZD1656 and AZD5658, as well as myeloperoxidase inhibitor AZD5904. Development progress includes AZD1656 and AZD5904 already completing Phase 1 clinical trials. Conduit Pharmaceuticals also notes that it intends to launch Phase 2 clinical trials for AZD1656 and AZD5658 this year. It intends to test their effectiveness as autoimmune disorder treatments. Conduit Pharmaceuticals CEO Dr. David Tapolczay said the following about the deal. “The potential of these assets to become important first-in-class medicines for patients is promising. Given the data from AstraZeneca’s clinical trials, we believe there is a strong rationale to initiate Phase II studies in multiple indications to progress to commercialization of these assets.” CDT Stock Jumps on AZN Agreement News of this license agreement brings with it heavy trading of CDT stock.

Conduit Pharmaceuticals secures AstraZeneca assets for autoimmune and infertility treatments. Phase II trials planned for 2024. Promising preclinical data, but potential shareholder dilution looms. Explore the deal''s impact on drug development.